Kronos Bio To Present At The 38th Annual J.P. Morgan Healthcare Conference

San Mateo, Calif., and Cambridge, Mass., January 10, 2020 – Kronos Bio, Inc., dedicated to the development of first-in-class therapies that modulate historically undruggable targets, today announced that Norbert Bischofberger, Ph.D., President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 10:30 a.m. Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

Launched in May 2018, the company announced a $105 million Series A financing in July 2019 to support the advancement of its Small Molecule Microarray platform (SMM). SMM is ideally suited for the rapid discovery of novel modulators or degraders of historically undruggable targets, such as transcription factors. Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity. SMM enables discovery of hits that act through a variety of mechanisms, including disruption of protein-protein or protein-DNA interactions, or indirect modulation of target protein activity by binding to co-factors or other protein complex members.

About Kronos Bio, Inc.

About Kronos Bio

Kronos Bio is a biopharmaceutical company that seeks to transform patient outcomes by targeting the oncogenic transcription factors and their associated transcriptional regulatory networks (“TRNs”) that define the cancer phenotype. We leverage deep capabilities in systems biology, chemical biology and clinical translational expertise in order to map these oncogenic TRNs, screen for small molecule modulators and identify selective vulnerabilities.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.

# # #

Kronos Bio Contact:
Christopher Wilfong
Chief Operating Officer
media@kronosbio.com